WINTON GROUP Ltd Buys New Shares in Ironwood Pharmaceuticals, Inc. $IRWD

WINTON GROUP Ltd bought a new stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 164,335 shares of the biotechnology company’s stock, valued at approximately $554,000. WINTON GROUP Ltd owned 0.10% of Ironwood Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in IRWD. Bank of America Corp DE increased its position in shares of Ironwood Pharmaceuticals by 248.3% in the 3rd quarter. Bank of America Corp DE now owns 11,695,544 shares of the biotechnology company’s stock valued at $15,321,000 after acquiring an additional 8,337,672 shares during the period. Millennium Management LLC grew its position in Ironwood Pharmaceuticals by 186.6% during the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock worth $9,349,000 after purchasing an additional 4,140,439 shares during the period. AQR Capital Management LLC grew its position in Ironwood Pharmaceuticals by 144.3% during the 2nd quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock worth $4,422,000 after purchasing an additional 3,641,762 shares during the period. Marshall Wace LLP grew its position in Ironwood Pharmaceuticals by 616.3% during the 2nd quarter. Marshall Wace LLP now owns 3,993,557 shares of the biotechnology company’s stock worth $2,875,000 after purchasing an additional 3,436,036 shares during the period. Finally, Jane Street Group LLC grew its position in Ironwood Pharmaceuticals by 740.5% during the 1st quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company’s stock worth $5,160,000 after purchasing an additional 3,092,475 shares during the period.

Insiders Place Their Bets

In related news, Director Alexander J. Denner sold 6,730,800 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $3.05, for a total value of $20,528,940.00. Following the transaction, the director directly owned 9,188,635 shares of the company’s stock, valued at approximately $28,025,336.75. This trade represents a 42.28% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 9.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Sunday, May 17th. Zacks Research downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, April 27th. Citizens Jmp increased their price target on Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 26th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $3.70 price target on shares of Ironwood Pharmaceuticals in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $6.23.

Ironwood Pharmaceuticals Trading Up 4.0%

Shares of Ironwood Pharmaceuticals stock opened at $3.35 on Thursday. The firm has a market capitalization of $546.25 million, a PE ratio of 5.58 and a beta of 0.25. Ironwood Pharmaceuticals, Inc. has a twelve month low of $0.61 and a twelve month high of $5.78. The firm’s 50-day moving average price is $3.82 and its 200 day moving average price is $3.87.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $106.51 million during the quarter, compared to analysts’ expectations of $92.11 million. Ironwood Pharmaceuticals had a net margin of 28.26% and a negative return on equity of 39.65%. On average, sell-side analysts predict that Ironwood Pharmaceuticals, Inc. will post 1.04 EPS for the current fiscal year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial?stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.